MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and Pandion Therapeutics, Inc. announced that the companies have entered into a definitive agreement, under which MSD, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash.